Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

LDL-mediated drug targeting.

P C de Smidt¹, T J van Berkel

¹Sylvius Laboratories, University of Leiden, The Netherlands.

Critical Reviews in Therapeutic Drug Carrier Systems

|January 1, 1990

Summary

Low-density lipoprotein (LDL) offers unique advantages as a drug carrier due to its lipid core and prolonged circulation. Its natural targeting to LDL receptors on tumor cells presents a promising strategy for drug delivery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Interactions of lipid-oligonucleotide conjugates with low-density lipoprotein.

Methods in molecular medicine·2011

Same author

ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis.

Current drug targets·2010

Same author

Efficient targeting of adenoviral vectors to integrin positive vascular cells utilizing a CAR-cyclic RGD linker protein.

Biochemical and biophysical research communications·2005

Same author

Scavenger receptor-like receptors for the binding of lipopolysaccharide and lipoteichoic acid to liver endothelial and Kupffer cells.

Journal of endotoxin research·2001

Same author

Midazolam is a phenobarbital-like cytochrome p450 inducer in rats.

The Journal of pharmacology and experimental therapeutics·2001

Same author

Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2001

Area of Science:

Biochemistry
Pharmacology
Nanotechnology

Background:

Low-density lipoprotein (LDL) serves as a natural liposome-like particle with a lipid core suitable for drug encapsulation.
Endogenous LDL exhibits prolonged circulation times and reduced uptake by the reticuloendothelial system compared to artificial liposomes.

Purpose of the Study:

To explore the potential and challenges of utilizing LDL as a drug delivery vehicle.
To evaluate LDL-mediated drug targeting strategies for cancer therapy.

Main Methods:

Discussion of LDL's in vivo behavior and receptor-mediated uptake mechanisms.
Critical assessment of methods for incorporating drugs into LDL particles.
Presentation of evaluation techniques for LDL-drug complexes.

Main Results:

LDL's lipid core can function as an effective drug reservoir.
Targeting LDL to tumor cells is feasible due to high LDL receptor expression in many cancers.
Endogenous LDL's pharmacokinetic profile is advantageous for drug delivery.

Conclusions:

LDL presents a viable and potentially superior alternative to liposomes for targeted drug delivery, particularly in oncology.
Further research and standardized evaluation methods are needed to optimize LDL-based drug delivery systems.

Related Experiment Videos